Berlin Biotech Raises €10M for Living Tissue Implants

A Berlin-based biotech company is pushing the boundaries of regenerative medicine, and it just secured the funding to back it up.

Cellbricks Therapeutics has announced €10 million in new capital, according to the company's press release. The round includes a €7 million seed round led by Silicon Roundabout Ventures, with participation from Germany's Federal Agency for Breakthrough Innovation (SPRIND) and existing investors ACT Venture Partners. More than €3 million in additional non-dilutive funding is currently under negotiation.

The money will accelerate preclinical validation of biofabricated human tissue implants, targeting major unmet needs in reconstructive surgery, wound healing, and trauma care. Think complex burns, blast injuries, or soft tissue defects where today's options, such as synthetic implants or invasive grafts, often fall short of restoring real biological function.

Cellbricks Therapeutics has developed a proprietary biofabrication platform capable of producing vascularized human tissue constructs. Its lead program targets adipose tissue implants, with potential applications in breast reconstruction as a biological alternative to synthetic solutions. Up to three preclinical animal studies are planned, generating the data needed to eventually move into human clinical trials.

The long-term ambition is significant: 3D-bioprinted viable human organs. But as the company's Co-CEO Alexander Leutner points out, that future is built one disciplined milestone at a time.

With roots in both Berlin and Boston, Cellbricks is operating at the intersection of two leading biotech ecosystems. The new capital positions the company to move from scientific promise to clinical proof.

---

Thinking about launching a business, setting up premises, or creating partnerships in Berlin?
We invite you to contact us.
Our team is ready to help you with our free consultation services.